CMMB
Chemomab Therapeutics Ltd.
stockNASDAQADR
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company's lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.05 | 2026-10-27 | +14.29% | -1.443 |
| 1M | 1.43 | 2026-10-02 | -16.08% | -0.970 |
| 3M | 1.62 | 2026-08-03 | -25.93% | 1.874 |
| 6M | 1.62 | 2026-05-04 | -25.93% | 1.385 |
| 1Y | 2.80 | 2025-11-03 | -57.14% | 1.774 |
| 2Y | 5.76 | 2024-11-04 | -79.17% | — |
| 5Y | 40.44 | 2021-11-03 | -97.03% | 1.056 |
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) stock price today is $1.20, and today's volume is 11,086. CMMB is up 1.695% today. The 30 day average volume is 99,629. CMMB market cap is $8.79M with 7.33M shares outstanding.